Oppenheimer analyst Jay Olson maintains $Marinus Pharmaceuticals (MRNS.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 38.6% and a total average return of 12.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Marinus Pharmaceuticals (MRNS.US)$'s main analysts recently are as follows:
Marinus Pharmaceuticals' Phase III study of oral ganaxolone in tuberous sclerosis complex rare epilepsy did not achieve the primary endpoint, failing to show a significant difference in placebo-adjusted percent change. Despite this, the company may still find 'leverageability' in its revenue stream from CDD. Following the stock's significant decline, there could potentially be an arbitrage opportunity.
The revision of the outlook on Marinus Pharmaceuticals to a more cautious stance comes in the wake of the Phase III trial of ganaxolone in tuberous sclerosis complex not achieving its primary endpoint. This outcome is coupled with the company's reported financial limitations and the indeterminate schedule for future actions.
Marinus Pharmaceuticals' Phase III trial of oral ganaxolone in treating tuberous sclerosis complex, a type of rare epilepsy, did not achieve its primary goal of reducing seizures. With no immediate catalysts anticipated until 2025, the outlook on the company has become more conservative.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
